“Autism”. The mere word is scary to most every parent. There are no known drugs for the treatment of autism. In fact, there are few, if any, products on the market that attempt to stop autism or counter-effect what is happening in the brain of the person with the disease. Autism spectrum disorders have a wide array of behaviors that result from it and the drugs that are prescribed are meant to deal with those symptoms, not the disease itself. Specific examples of the symptoms can include, but are not limited to:
- Bi-polar disorders
- Anxiety (or depression)
- Obsessive-compulsive disorder
- Attention deficit
- Behavioral issues
There are many drugs that treat these symptoms including Prozac, Wellbutrin, Ritalin, haloperidol and Risperdone, which is still relatively new and without long-term studies being concluded for side effects. Regardless of which symptom these pharmaceuticals treat, they all have one thing in common; they only treat the symptom, not the underlying cause.
On Monday, March 29, 2010, you will be able to read about a company that is attempting to solve this long-time problem. Cellceutix Corporation is seeing positive results in the studies of their compound KM-391 that will be issued in a press release on that day.
To quote the Cellceutix website: “Preliminary testing of KM-391 in mice revealed that the test animals showed a significant increase in serotonin uptake compared to controls, with no apparent side-effects in the long-term administration of KM 391 in mice. The equalization of serotonin uptake is considered by many researchers as an important development in the treatment of autism spectrum disorders.”
The Cellceutix research team, headed by Chief Scientific Officer, Dr. Krishna Menon, has seen their small molecule have a direct impact on neonatal serotonin depletion and the plasticity of the brain in Wistar rat pups used in their experiments. Using three groups in their studies, the team replicated some of the leading features observed in autism in the rat pups at birth and then proceeded to conduct the studies on those features with treatment of KM-391. The results have been extremely positive. Cellceutix Corporation will be continuing to move forward with patents and eventual clinical testing of this possible solution to the root causes of autism.
Cellceutix Corporation, based in Waverly MA, is a publicly traded, developmental biotechnology company on the OTC Bulletin Board trading under the ticker CTIX. Cellceutix was co-founded in 2007 by a 26-year veteran of Pfizer, Inc., Mr. George Evans. Mr. Evans was General Counsel of Pfizer’s worldwide prescription drug unit and integral in the development and marketing of many of Pfizer’s pharmaceutical products before leaving to start Cellceutix with Dr. Krishna Menon. Dr. Menon’s list of biotechnology accolades throughout his almost 40 years in the field of research is impressive, to say the least, including being a President’s Recognition Award recipient while at Eli Lilly. With an extensive background in oncology research, Dr. Menon has been a lead researcher in several drugs that have gone on to produce billions of dollars in revenues for their respective companies.
Cellceutix owns the rights to 8 different compounds that they are developing to treat a variety of major diseases in their own, innovative manners. Their flagship product, Kevetrin, has been shown with animal subjects to be effective in the treatment of cancer in subjects that have proven to be resistant to standard, proven cancer treatments on the market today. Cellceutix is in the process of aligning Phase I studies and patenting processes for Kevetrin.